A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

NCT06280105 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Cadonilimab+regorafenib

Sponsor

Meng Chao Hepatobiliary Hospital of Fujian Medical University